Peter Jenner
London
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Peter Jenner
Supervised Machine learning and Molecular docking modeling to Identify Potential Anti-Parkinson’s Agents
The prevalence of Parkinson's disease (PD), the second most prevalent neurodegenerative illness in the world, is roughly 0.5–1% among those aged 65–69 and increases to 1-3 percent among those aged 80 and above 1, 2. PD causes significant behavioral and cognitive impairment. It was first defined by Jean-Martin Charcot after James Parkinson's 1817 description [3]. Through a non-dopaminergic mechanism, adenosine A2A receptor antagonists offer a novel approach to treating the symptoms of Parkinson's
Stalevo®: A pioneering treatment for OFF periods in Parkinsons disease
Abstract Enzymatic metabolism is the key determinant of the overall bioavailability, brain penetration and efficacy of levodopa in the treatment of Parkinson's Disease (PD). Enzyme inhibitors in the form of peripheral dopa-decarboxylase inhibitors and monoamine oxidase type-B inhibitors have been successfully employed to maximize the utility of levodopa in both early- and late-stage PD.
The 20th anniversary of the first clinical use of Stalevo®
EDITORIAL This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.1111/ene.15996. No abstract is available for this article. The full text of this article hosted at iucr.org is unavailable due to technical difficulties.
Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone
1. Introduction Levodopa is the most efficacious drug for the treatment of the motor symptoms of Parkinson’s disease (PD) and the ‘gold standard’ therapy required by almost every patient affected by this common neurodegenerative disorder [1,2]. However, its utility is often limited by the development of motor fluctuations (e.g. ‘wearing-off,’ ‘ON-OFF’) and motor complications (dyskinesia – chorea, dystonia, athetosis) [3].
Istradefylline - a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease
The treatment of Parkinson’s disease (PD) has been dominated by dopamine replacement therapy for over 60 years. Following the introduction of levodopa in the 1960s, a range of dopamine agonist drugs (e.g. apomorphine, bromocriptine, cabergoline, pergolide, ropinirole, pramipexole, rotigotine) were added to (and some subsequently removed from) the PD armamentarium [Citation1, , , et al.
‘Dopamine agonist Phobia’ in Parkinson’s disease: when does it matter? Implications for non-motor symptoms and personalized medicine
ABSTRACT Introduction Dopamine agonists have been widely used to treat patients with Parkinson’s disease, but concerns related to their well-known side effects might prevent their use even when indicated. In this review, the authors describe for the first time the concept of ‘Dopamine Agonist Phobia’, a pharmacophobia that the authors believe might affect clinicians, and they provide evidence of the benefits of dopamine agonists, focusing on non-motor symptoms.
‘Dopamine agonist Phobia’ in Parkinson’s disease: when does it matter? Implications for non-motor symptoms and personalized medicine
The use of dopamine agonists in very elderly patients with Parkinson’s disease • Original paper assessing the efficacy and tolerability of dopamine agonists in elderly Parkinson’s Disease patients.
Apomorphine infusion in advanced Parkinson disease
The TOLEDO study provides new evidence to support the use of subcutaneous apomorphine infusion to control motor fluctuations in patients with advanced Parkinson disease. The findings should encourage neurologists to consider implementing apomorphine infusion or other device-aided therapies earlier in the disease course, before the emergence of troublesome dyskinesias.
The Future of Parkinson’s Treatment - Personalised and Precision Medicine
Levodopa therapy and other dopamine replacement therapies (DRTs) have remained the cornerstone for the treatment of Parkinson’s disease (PD) since the 1960s.1 Many motor symptoms of PD can be partially reversed by DRT as well as more invasive therapies such as deep brain stimulation (DBS) of the subthalamic nucleus. However, many challenges remain both in the short and long term.
Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected
I have Parkinson's. I would like you to address the following symptoms that bother me the most: sleep, pain and then my movement disorder. James Parkinson recognised the implications and importance of motor Parkinson's disease (PD) in 1817 and highlighted key non-motor symptoms, such as sleep dysfunction, dysautonomia, cognitive and neuropsychiatric issues.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Peter
Contact Peter, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack